Drugs that increase central noradrenergic activity have been shown to enhance the rate of recovery of motor function in preclinical models of brain damage. Less is known about whether noradrenergic agents can improve the extent of motor recovery and whether such improvement can be sustained over time.
1.

Introduction
Stroke is a devastating neurological event that often results in permanent deficits of motor function (Langhorne et al., 2009) . Physical therapy (PT) is the mainstay of rehabilitative treatment aimed at improving motor disability after stroke, but there is still a need for improved rehabilitative strategies. A great deal of investigation has focused on pharmacological means of improving long-term motor outcome. To this end, drugs that enhance central noradrenergic activity have shown some promise for promoting motor recovery following brain injury (Berends et al., 2009; Boyeson and Feeney, 1990; Feeney et al., 2004; Goldstein, 2006) .
Clinical observations indicate that norepinephrine re-uptake inhibitors lead to improved acquisition of motor skills in healthy volunteers and in stroke patients (Plewnia et al., 2004; Foster et al., 2006; Zittel et al., 2007) . Preclinical studies indicate that a variety of drugs that enhance central noradrenergic activity promote motor recovery following brain damage while drugs that block noradrenergic activity impair motor recovery. For example, blockade of alpha-1 adrenoceptors or depletion of brain norepinephrine significantly slows recovery of function (Feeney et al., 1982; Feeney and Westerberg, 1990; Feeney et al., 2004; Boyeson et al., 1992; Goldstein and Bullman, 2002) . In contrast, the psychomotor stimulant amphetamine, which induces the neuronal release of norepinephrine, dopamine and to a lesser extent serotonin, improves forelimb motor function following brain injury (Adkins and Jones, 2005; Feeney et al., 1981; Gilmour et al., 2005; Hovda and Fenney, 1984; Papadopoulos et al., 2009) . Clinical studies also suggest that amphetamine can improve motor function, although results are more controversial (Crisostomo et al., 1988; Goldstein, 2009; Martinsson et al., 2007) .
One means of increasing central noradrenergic activity that has shown promise in preclinical motor rehabilitative strategies is through alpha2-adreneceptor antagonists. Alpha2-adrenoceptors serve as cell body and nerve terminal inhibitory autoreceptors, the blockade of which can lead to enhanced synaptic availability of norepinephrine (Gobert et al., 2004) . Relatively non-selective alpha2 adrenoceptor antagonists, such as yohimbine, did not show great rehabilitative potential following sensorimotor cortex lesions in early pre-clinical studies (Feeney and Westerberg, 1990) . However, the more selective alpha2-adrenoceptor antagonist atipamezole (ATI) has recently been shown to improve the rate at which motor performance returns to baseline levels following transient middle cerebral artery occlusion (MCAO) in rats, albeit with some variability (Newman-Tancredi et al., 1998; Pertovaara et al., 2005; Butovas et al., 2001; Haapalinna et al., 1997; Karhunen et al., 2003; Puurunen et al., 2001; Jolkkonen et al., 2000) .
Despite these promising results in improving the rate of recovery there is no understanding as to whether atipamezole could improve the extent of motor improvement following stroke, because motor deficits were not persistent in these earlier studies. Thus, it remains to be determined whether alpha2-adrenoceptor antagonists can lead to sustained motor improvement after stroke.
The aim of the present study was to determine how sub-acute (i.e. 1 week) treatment with the α 2 -adrenoceptor antagonist atipamezole affects long-term (i.e. 8 weeks) motor performance following permanent middle cerebral artery occlusion as a model of stroke. Additionally the importance of combining rehabilitation with atipamezole treatment was studied. We chose two behavioral tests, the forelimb reaching test and the ladder rung walk test, which require skilled forelimb use and which show consistent impairment through the course of at least 8 weeks in this stroke model (Whishaw, 2000; Papadopoulos et al., 2009; Ramic et al., 2006) .
Results
Lesion analysis
All lesions impinged upon the forelimb area of the sensorimotor cortex ipsilateral to the occluded MCA with no obvious signs of damage to underlying subcortical tissue. Despite the trend for animals receiving atipamezole and/or rehabilitation to exhibit larger lesions, no significant difference was found in infarct volume among the 4 different treatment groups (Table 1, F 3,36 = 1.73, p = 0.18).
Skilled forelimb reaching
On Postoperative Day 2, before administering any drug or focused activity sessions, reaching performance in all groups showed a marked deficit resulting in a range of mean reaching success of 2.5 -3.5 pellets/ 20 attempts with no significant difference among groups (F 3,36 = 0.14, p = 0.93). Over the course of 8 weeks of testing all treatment groups improved in reaching performance, but to varying degrees ( Fig. 1) . A one-way ANOVA on Ranks established a significant treatment effect (H = 20.6 with 3 degrees of freedom, p<0.001). Post hoc analysis
showed that overall reaching performance in rats receiving short-term atipamezole combined with rehabilitation (ATI/REHAB) was significantly better than rats receiving vehicle plus rehabilitation (VEH/REHAB) or vehicle controls (i.e. no rehabilitation). The difference between ATI/REHAB and animals receiving atipamezole without rehabilitation (ATI/CON) did not reach significance.
At 8 weeks a comparison between the endpoint observation and pre-operative performance was carried out to determine whether recovery to baseline performance had occurred (Fig. 2) . Twoway ANOVA revealed a significant effect of MCAO surgery (F 1,33 = 77.97, p<0.001), a significant effect of treatment (F 3,33 = 4.46, p = 0.01), but no significant interaction (F 3,33 = 2.69, p = 0.06). Post-hoc comparison revealed that endpoint performance in all groups was significantly lower than pre-operative performance (p<0.001 for all groups except ATI/REHAB, p=0.02). However, post-hoc comparison of treatment effect at the 8 week endpoint revealed that the ATI/REHAB group performed significantly better than all other groups (p<0.05).
Ladder rung walk
On Postoperative Day 2 all groups showed a marked deficit in accurate placement of the contralesional forelimb, resulting in a range of mean performance of 2.9 -4.2 errors/10 steps across all groups. Although there was a trend toward fewer errors by animals allocated to the atipamezole groups compared to those in the vehicle groups the mean difference in performance did not reach statistical significance (F 3,36 = 2.47, p = 0.08). Fig. 3 shows that, similar to reaching performance, ladder walk performance improved to some extent in all groups over 8 weeks. A one-way ANOVA on Ranks demonstrated a significant treatment effect (H = 63.3 with 3 degrees of freedom, p<0.001). Post-hoc analysis revealed a number of statistical differences among groups. Importantly, overall performance in the ATI/REHAB group was significantly better than any other group. Unlike the results for the reaching task, overall ladder walk performance of the ATI/CON group was significantly better than vehicle-treated animals regardless of the presence of rehabilitation (i.e better than VEH/CON or VEH/REHAB group).
At 8 weeks a comparison between the endpoint observation and pre-operative performance was carried out to determine whether recovery to baseline performance in the ladder rung walk had occurred (Fig. 4) . Two-way ANOVA comparing endpoint (8 week) performance vs. preoperative performance revealed a significant effect of MCAO surgery (F 1,33 = 14.28, p<0.001), and a significant interaction (F 3,33 = 5.13, p = 0.005), but no significant treatment effect (F 3,33 = 1.13, p = 0.35). Neither vehicle-treated group recovered to baseline (i.e. pre-operative)
performance by 8 weeks post-op. By comparison, ladder rung walk performance at 8 weeks had recovered to baseline (i.e. pre-operative) performance in animals receiving atipamezole regardless of whether or not they received rehabilitation (Fig. 4) . Post-hoc comparison of treatment effect at the 8 week endpoint revealed that the ATI/REHAB group performed significantly better than VEH/CON or VEH/REHAB (p<0.006, Student-Newman-Keuls).
Discussion
The main finding of this study is that subacute administration of atipamezole, in combination with physical rehabilitation (i.e. focused activity plus enriched environment), led to a significantly greater degree of motor improvement following stroke as compared to rehabilitation alone. Importantly, motor improvement in both the forelimb reaching task and ladder rung walk was apparent at 8 weeks following stroke (7 weeks following cessation of atipamezole), indicating a long-lasting effect of drug treatment. These results are similar to what we found in a previous study using the catecholamine releasing agent D-amphetamine sulfate (Papadopoulos et al., 2009) . When paired with physical rehabilitation amphetamine led to enhanced motor improvement following stroke that was significantly greater than rehabilitation alone.
Interestingly, amphetamine/rehabilitation induced a recovery to baseline (i.e. pre-operative) performance in both motor tasks at 8 weeks. In the present study, atipamezole paired with physical rehabilitation led to motor recovery to baseline at 8 weeks only in the ladder rung walk.
This minor difference in outcome between the two studies may reflect differences in mechanism of action of the two drugs and the degree to which noradrenergic activity is enhanced.
Atipamezole is an alpha2-adrenergic antagonist that blocks the activation of presynaptic autoreceptors on noradrenergic neurons (Gobert et al., 2004; Haapalinna et al., 1997; NewmanTancredi et al., 1998; Pertovaara et al., 2005) . Thus the degree to which atipamezole increases the synaptic availability of norepinephrine depends, in part, on the level of activity of noradrenergic neurons. Amphetamine induces the neuronal release of norepinephrine regardless of the level of noradrenergic neuronal activity and it might be expected to cause greater release of norepinephrine (Geranton et al., 2003) . Additionally, atipamezole is more selective than amphetamine in its ability to increase the synaptic availability of norepinephrine without affecting the dopaminergic system (Scheinin et al., 1988; Gobert et al., 2004) . Preliminary studies from our lab (not shown) and published reports have shown that dopamine D2 blockade with haloperidol can impair motor recovery or prevent amphetamine-induced motor improvement, suggesting that dopamine may also be an important contributor to rehabilitative drug action (Feeney and Hovda, 1983; Goldstein and Bullman, 2002) . Along these lines, it is interesting that the noradrenergic releasing agent, methylphenidate, which has greater selectivity but lower efficacy for releasing norepinephrine, has not been shown to have a profound impact on motor recovery in preclinical or clinical studies of brain damage, but may improve cognitive function (Grade et al., 1998; Kajs-Wyllie, 2002; Kline et al., 1994; Liepert, 2008) . It would be interesting to determine whether more robust improvement in performance on the reaching task by atipamezole (and other drugs that rely more exclusively on noradrenergic enhancement) could be achieved if paired with physical activity that requires more forelimb and digit dexterity such as the pasta handling test.
Our findings extend the work of previous studies in which it was shown that atipamezole can improve the rate of motor functional recovery following ischemic brain damage. The data from these studies suggest that noradrenergic-enhanced motor recovery following stroke is best achieved in tests requiring use-dependent practice (Jolkkonen et al., 2000; Puurunen et al., 2001; Butovas et al., 2001; Karhunen et al., 2003) . In these studies rats received a transient middle cerebral artery occlusion (MCAO) followed by daily motor testing for the first week following stroke and then semi-regular testing (every 3-5 days) for up to 3 more weeks.
Administration of atipamezole prior to motor testing increased the rate at which motor scores in limb placing and foot-slip tests returned to pre-operative values. However, the motor deficits induced by transient MCAO were not shown to persist and all experimental groups recovered to baseline performance by the end of each study. Moreover, there was little indication of atipamezole-induced improvement in forelimb use asymmetry in the cylinder test, which was performed only once during the first week post-stroke and once again at 3 weeks post-stroke.
Limb use asymmetry in the cylinder test is relatively long lasting and there is little evidence that animals develop compensatory motor strategies (Schallert et al., 2000) . These previous findings are important in that they suggest that noradrenergic enhancement of motor function following stroke may require the learning of new motor strategies or repeated motor testing. Accordingly, clinical studies have shown that noradrenergic enhancement improves the acquisition of motor skills (Plewnia et al., 2004; Foster et al., 2006; Zittel et al., 2007) , providing the basis for suggesting that faster motor improvement caused by enhanced noradrenergic activity is the result of enhanced acquisition of motor skills. However the previous preclinical studies with atipamezole could not address the issue of whether such treatment would be effective in reversing persistent motor deficits. Our present study addresses this matter by employing a permanent MCAO model of stroke that leads to long lasting deficits in skilled forelimb use. Using this model, motor deficits lasted throughout the observation period of 8 weeks post-stroke. Our design was to administer atipamezole prior to focused activity sessions to avoid the potential confound of a direct influence on performance in the motor assessment tasks. Atipamezole was administered after behavioral assessment and 15 min prior to the start of focused activity sessions in order to coincide with the timing of increased synaptic norepinephrine (Gobert et al., 2004; Pertovaara et al., 2005) . Under these conditions atipamezole improved motor performance to an extent greater that that seen in respective vehicle-treated groups. While our experimental design rules out a direct effect of atipamezole on motor performance during the assessment tasks, it should be noted that the focused activity consisted of exercises with similar forelimb motor-specific requirements (i.e. grasping, grip strength, placement, coordination) as the behavioral tests employed. These tasks are similar to the complex motor skills training (i.e. "acrobatic task") that induces structural plasticity in the intact motor cortex of rats receiving a sensorimotor cortex lesion on the other side (Jones et al., 1999) . Following lesion, acrobatic rats showed evidence of increased synaptogenesis compared to rats that were simply required to run in an alley for a similar duration as the acrobatic task. These data suggest that the level of complexity of physical training, which may introduce a learning component to the task, is an important variable to be considered. Given the discussion above related to noradrenergic enhancement of motor skills, it is possible that atipamezole enhanced the learning of compensatory motor strategies, which could then be generalized to the behavioral tests (e.g. see Whishaw, 2000; Bury and Jones, 2002 ).
The present finding of sustained (i.e. lasting 8 weeks) motor improvement following short-term atipamezole suggests that, like amphetamine, atipamezole may be capable of inducing profound and persistent changes in intracellular signaling, gene transcription as well as altered synaptic morphology (Robinson and Kolb, 1999; Nestler, 2001; Park et al., 2002) . Several studies have shown that norepinephrine reuptake inhibiting antidepressants alter gene transcription related to synaptic plasticity in a similar manner (Laifenfeld et al., 2002; Laifenfeld et al., 2005; Schmidt et al., 2008) . Additionally, drugs that enhance central noradrenergic activity have a profound effect on the expression of a variety of neurotrophic factors such as basic fibroblast growth factor (bFGF), brain derived neurotrophic factor (BDNF) and glial cell derived neurotrophic factor (Chen et al., 2007; Garcia et al., 2003; Juric et al., 2008; Mannari et al., 2008; Rizk et al., 2006; Schmidt et al., 2008; Bachis et al., 2008; Flores et al., 1998; Riva et al., 1998) . Of special interest is bFGF, which is a potent neurotrophic factor that has been shown to enhance recovery of motor function following ischemic brain damage, presumably by contributing to synaptogenesis (Baird, 1994; Patel and McNamara, 1995; Kawamata et al., 1997a; Kawamata et al., 1997b; Kawamoto et al., 1999; Rowntree and Kolb, 1997) . Following brain damage, bFGF expression shows a persistent increase that can last for weeks (Takami et al., 1993; Reilly and Kumari, 1996) and which can be localized to both neuronal and astrocyte populations (Chadi et al., 1993; Wei et al., 2000) . Activation of astrocytes may be one mechanism by which noradrenergic activity induces upregulation of growth factors. It has long been known that both alpha1-and beta-adrenergic receptor subtypes reside on astrocytes and mediate an increase in neurotrophins such as bFGF and BDNF (Junker et al., 2002; Juric et al., 2008; Kimelberg, 1995; Hertz et al., 2004) . The ability of noradrenergic agents to stimulate neurite outgrowth in cell culture has been shown (Laifenfeld et al., 2002; Kwon et al., 1998; Park et al., 2002) and our previous study demonstrated that amphetamine treatment paired with rehabilitation induced neurite outgrowth from corticoefferent pathways of the contralesional hemisphere (Papadopoulos et al., 2009) . Unfortunately, technical difficulties in the present study prevented us from determining whether improved motor outcome with atipamezole plus rehabilitation was associated with corticoefferent axonal sprouting. Nevertheless, studies are currently underway to delineate the possible neurobiological mechanisms mediating noradrenergic-enhanced neurite outgrowth in vitro as well as in vivo.
In summary the present findings indicate that short-term treatment with an alpha2 adrenoceptor antagonist can lead to enhanced long-term motor recovery following ischemic stroke when paired with focused physical therapy. These findings, combined with the observation that moderate blockade of alpha2 adrenoceptors appears to induce less profound sympathetic activation than amphetamine (Pertovaara et al., 2005; Schmidt et al., 1997; Martinsson et al., 2007) , suggest that increasing central noradrenergic tone through inhibition of alpha2-adrenergic inhibitory autoreceptors may be a useful adjunct in the treatment of stroke. However, care should be taken when extrapolating our results in animals to the design of patient clinical trials. Studies are underway to delineate the pharmacological and neurobiological mechanisms involved.
Experimental Procedures
Animals
Adult male Long Evans, black-hooded rats (250-300 g) were maintained in a temperature and humidity controlled room under a 12:12-h light/dark cycle. Food intake was moderately restricted throughout the study to maintain body weight at 95% of ad libitum weight. Water was available ad libitum. All experimental procedures were approved by the Institutional Animal Care and Use Committees.
Housing/Rehabilitation/Drug Administration
Rats were randomly allocated to different experimental groups with differing housing conditions Atipamezole HCl was obtained as a sterile injectable solution (Antisedan 5 mg/ml, Orion Corporation) and diluted to 1 mg/ml with 0.9% sterile saline. All animals received either atipamezole (1 mg/kg, s.c.) or vehicle (0.9% sterile saline) in a volume of 1 ml/kg on post-op days 2 -8 following MCAO. Animals receiving focused activity began the session fifteen minutes following injection, which coincides with maximal serum concentration of the drug (Pertovaara et al., 2005) .
Training/Behavioral Testing
All animals were trained on the skilled forelimb reaching task and familiarized with the ladder rung walk test to assess deficits in performance of the impaired (i.e. contralateral to stroke) forelimb as previously described (Papadopoulos et al., 2009) . Investigators performing behavioral testing were blinded to the treatment groups. Skilled forelimb reaching involved placing an animal in a transparent Plexiglas chamber (30 x 36 x 30 cm) and training it to reach through a window (1.5 x 3 cm) to retrieve small sucrose pellets (45 mg; Bilaney Consultants, Frenchtown, NJ) placed on a platform at a distance of 1 cm. During the initial days of training, limb preference was determined and placement of pellets was adjusted to favor the use of the preferred forelimb. Prior to surgery, baseline performance (defined as the average of the last three testing sessions of the preoperative testing) was established. Success was defined as an animal grasping the pellet on the first attempt and placing it into the mouth (i.e. "first reach success"). The pre-operative criterion was at least 16 successes in 20 attempts for 3 consecutive days. Animals that reached criterion were randomly allocated to experimental groups (see Table   1 ) prior to MCAO surgery. Animals that failed to reach criterion were not used. Following MCAO surgery animals were tested on the skilled forelimb reaching task beginning the first day post-operatively and then daily (Mon -Fri) for 8 weeks. Each testing session consisted of 20 reaching opportunities using the preferred/impaired forelimb. Attempts using the non-preferred forelimb were not included in analyses. A maximum time limit of 5 minutes/testing session was given.
In the ladder rung walk animals were scored for their ability to cross a 1 m long horizontal metalrung runway with varying gaps of 1-2 cm between the rungs (Metz and Whishaw, 2002) . All animals underwent 3 familiarization sessions with the apparatus prior to pre-operative baseline testing. Sessions were then videotaped and scored at 1 day pre-op to determine baseline performance. Following MCAO surgery and allocation to experimental groups (see Table 1) animals were videotaped and scored on the ladder rung walk on the 2 nd day post-op and then weekly for 8 weeks. A forelimb foot error was defined as a complete miss or slip from the rung.
The mean preoperative scores for all experimental groups were approximately 1 foot error per 10 steps. Baseline and post-operative testing sessions consisted of 3 runway crossings. The total number of errors and steps by the preferred forelimb in each session was counted. An error frequency was calculated by dividing the sum total of steps for all 3 crossings in a session by the sum total of errors for the same 3 crossings in that session. Only data representing the performance of the impaired forelimb were analyzed.
Stroke surgery
All animals underwent MCAO on the side opposite the preferred reaching limb as described previously (Papadopoulos et al., 2009) . Animals were anesthetized with sodium pentobarbital (50 mg/kg; i.p.). Bilateral common carotid arteries (CCA) were isolated, a vertical 2 cm long incision was made between the eye and ear, and the temporalis muscle was retracted. A burr hole was made to expose the MCA and it was permanently occluded with a 10-0 suture. The CCA ipsilateral to the MCAO was permanently occluded with a 4-0 suture and the contralateral CCA was temporarily occluded for 45 min. The wounds were then closed and animals warmed under a heating lamp until they awoke.
Lesion analysis and exclusion criteria
At the end of the study animals were overdosed with sodium pentobarbital (100mg/kg; i.p.) and perfused transcardially with 4% paraformaldehyde. Brains and spinal cords were removed, placed in 30% sucrose for 1-2 days, embedded in OCT freezing compound (Miles, Inc), frozen, and stored at -80 0 C. Coronal cryosections (50 μm thick) were processed with Nissl stain. Stroke volume was quantitatively analyzed on Nissl stained sections (+4.7 to -5.2 mm from bregma according to Paxinos and Watson) using NIH image as described previously (Papadopoulos et al., 2009) . Stroke size was expressed as the percent difference in volume between the infarcted hemisphere and the contralesional intact hemisphere. The entire hemisphere including subcortical tissue was included in the analyses. Animals were excluded from all statistical analyses if the lesion was found not to impinge on the forelimb region of the sensorimotor cortex, and/or if subcortical damage was observed.
Statistics
Data was analyzed using SigmaStat (Systat Software Inc.). Stroke size was analyzed by one-way ANOVA. Skilled forelimb reaching and ladder rung walking were analyzed independently using a one-way ANOVA on ranks for overall treatment effect since data failed either the normality End point analysis -At eight weeks following MCAO, reaching performance in the ATI/REHAB groups was significantly better than all other groups (*, p<0.05, two-way ANOVA followed by Student-Newman-Keuls). A two-way repeated measures ANOVA indicated that all treatment groups still displayed significant deficits in reaching when compared to pre-operative performance (+, p<0.05, Student-Newman-Keuls), which demonstrates that full recovery to baseline performance in the forelimb reaching task was not achieved. Data represent the mean ± SEM for following number of animals/group: VEH/CON = 9, VEH/REHAB = 9, ATI/CON = 9, ATI/REHAB = 10. Short-term atipamezole enhances motor improvement in ladder rung walking after permanent MCAO regardless of physical rehabilitation.
Time course of motor performance-At Day 2 Post-op, prior to any treatment, the mean deficit in skilled forelimb placement was not significantly different among groups (F 3,36 = 2.47, p = 0.08).
A one-way ANOVA on Ranks established an overall treatment effect (H = 63.3 with 3 degrees of freedom, p<0.001) and Dunn's post-hoc test established that ATI/REHAB produced a significant overall enhancement in ladder rung walking performance compared to all other treatment groups (*, p<0.05). Post-hoc analysis also revealed a significant overall enhancement in performance in ATI/CON compared to either vehicle-treated group (+, p<0.05). Data represent the mean ± SEM for following number of animals/group: VEH/CON = 9, VEH/REHAB = 9, ATI/CON = 9, ATI/REHAB = 10. End point analysis -At eight weeks following MCAO, ladder walk performance following ATI/REHAB was significantly better than either vehicle-treated group (*, p<0.05, two-way ANOVA followed by Student-Newman-Keuls). A two-way repeated measures ANOVA indicated that the ATI/CON and ATI/REHAB groups achieved end-point performance that was not different from pre-operative levels while both vehicle-treatment groups still displayed significant deficits when compared to pre-operative performance (+, p<0.05, Student-NewmanKeuls). Data represent the mean ± SEM for following number of animals/group: VEH/CON = 9, VEH/REHAB = 9, ATI/CON = 9, ATI/REHAB = 10.
